
FDA Approves Adrabetadex for Infantile-Onset Niemann-Pick Type C
Key Takeaways
- FDA requested data/documentation updates, triggering a major amendment and a 3-month PDUFA extension despite priority review and prior breakthrough therapy designation.
- Orphan drug and rare pediatric disease designations were granted, reflecting high unmet need in infantile-onset NPC and potential eligibility for pediatric priority review voucher pathways.
FDA approved adrabetadex for infantile-onset Niemann-Pick disease type C after survival data showed 84% vs 42% 5-year survival with treatment.
Adrabetadex (VTS-270; Beren Therapeutics) was recently ___ by the FDA to treat infantile-onset Niemann-Pick disease type C (NPC).1
The first-in-class, disease-modifying approach is an investigational cyclodextrin therapy designed to increase intracellular cholesterol trafficking in patients with NPC.2
Adrabetadex’s Path Through FDA Review
The delayed decision came less than a year after Beren Therapeutics’ new drug application (NDA) was accepted for
Adrabetadex was also granted orphan drug and rare pediatric disease designations, further underscoring the treatment need within this disease.4
Understanding Infantile-Onset Niemann-Pick Disease Type C
NPC is a
Infantile-onset NPC refers to children who first experience neurological symptoms between the ages of 0 and 6 years. Onset before age 2 is associated with more rapid progression and poorer outcomes, with a mean survival of about 5.6 years, compared with about 13.4 years for onset between ages 2 to younger than 6 years.2,4
Survival Benefit Seen in WORLDSymposium Data
Earlier findings on the drug’s survival and disease progression benefits were presented at the 22nd Annual WORLDSymposium, held February 2-6, 2026, in San Diego, California.5 Eligible participants were pooled from the phase 2b/3 trial with open-label extension (VTS301: Parts A/B [
The data showed adrabetadex was associated with a 71% lower risk of death compared with matched external controls (HR, 0.289; 95% CI, 0.141-0.593; P < .0001). The 5-year overall survival (OS) rate was 84% with adrabetadex vs 42% among external controls.5
Overall, infantile deaths were also lower in the adrabetadex group (17 [23.6%] vs 44 [61.2%]). The treatment also reduced the annual rate of disease progression by 43%, from 1.34 units/year before treatment to 0.76 units/year during treatment (difference, –0.58 units/year; 95% CI, –0.98 to –0.18; P = .0055).5
References
1.
2. Beren Therapeutics announces FDA acceptance of its new drug application for adrabetadex in infantile-onset Niemann-Pick disease type C. Beren Therapeutics. February 23, 2026. Accessed November 17, 2026.
3. FDA extends Beren’s rare disease review after info request, further stretching saga. Fierce Biotech. May 28, 2026. Accessed November 17, 2026.
4. FDA grants breakthrough therapy designation to investigational drug adrabetadex for individuals with infantile-onset Niemann-Pick disease type C. Beren Therapeutics. December 9, 2025. Accessed November 17, 2026.
5. Berry-Kravis E, Keller LH, Jiao L, et al. Substantial survival benefit and slowing of disease progression with adrabetadex treatment in individuals with infantile-onset Niemann-Pick disease type C (NPC). Presented at: 22nd Annual WORLDSymposium; February 2-6, 2026; San Diego, CA. Poster LB-13.
Related to this article








